Benzinga · Aug 21, 2026
MAIA Biotechnology Files $150M Mixed Shelf Offering
https://www.sec.gov/Archives/edgar/data/1878313/000149315226039679/forms-3.htm
MA
NASDAQ · MAIA
MAIA Biotechnology, Inc.
Healthcare · Biotechnology
$1.31
Down-$0.01 (-0.76%)
Updated Sep 11, 2026, 8:53 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 60.55M
- P/E ratio
- -3.06
- Dividend yield
- 0.00%
- 52-week range
- $0.87 – $3.19
- Volume
- 333.09K
- Avg. volume
- 630.4K
Price performance
MAIA price history
1M range · 20 trading sessions · Daily adjusted prices
MAIA closed at $1.31 after 20 trading sessions, down 2.24% for the selected period.
- Last close
- $1.31
- Period change
- -2.24%
- Period low
- $1.30
- Period high
- $1.41
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $1.36 | $1.36 | $1.30 | $1.31 | 333.09K |
| Sep 9, 2026 | $1.33 | $1.38 | $1.325 | $1.33 | 553.9K |
| Sep 8, 2026 | $1.32 | $1.348 | $1.30 | $1.31 | 226.66K |
| Sep 4, 2026 | $1.35 | $1.35 | $1.30 | $1.32 | 243.25K |
| Sep 3, 2026 | $1.38 | $1.40 | $1.31 | $1.33 | 470.79K |
| Sep 2, 2026 | $1.40 | $1.46 | $1.355 | $1.37 | 865.84K |
| Sep 1, 2026 | $1.30 | $1.32 | $1.28 | $1.30 | 331.35K |
| Aug 31, 2026 | $1.33 | $1.33 | $1.295 | $1.31 | 258.68K |
| Aug 28, 2026 | $1.38 | $1.38 | $1.32 | $1.33 | 361.32K |
| Aug 27, 2026 | $1.40 | $1.40 | $1.37 | $1.38 | 263.1K |
| Aug 26, 2026 | $1.41 | $1.471 | $1.385 | $1.39 | 558.01K |
| Aug 25, 2026 | $1.40 | $1.46 | $1.36 | $1.41 | 943.17K |
| Aug 24, 2026 | $1.40 | $1.40 | $1.325 | $1.35 | 228K |
| Aug 21, 2026 | $1.38 | $1.405 | $1.35 | $1.39 | 379.84K |
| Aug 20, 2026 | $1.37 | $1.40 | $1.36 | $1.38 | 223.26K |
| Aug 19, 2026 | $1.40 | $1.42 | $1.38 | $1.39 | 337.17K |
| Aug 18, 2026 | $1.39 | $1.40 | $1.36 | $1.37 | 235.78K |
| Aug 17, 2026 | $1.40 | $1.40 | $1.35 | $1.39 | 266.98K |
| Aug 14, 2026 | $1.34 | $1.40 | $1.34 | $1.40 | 569.03K |
| Aug 13, 2026 | $1.36 | $1.385 | $1.34 | $1.34 | 179.09K |
Latest MAIA news
The latest Smart Investors Daily articles mentioning MAIA.
Stock researchCompany · Overview
MAIA research
Overview
Company profile and research snapshot.
Company profile
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $12.38
- Implied upside
- —
- Analysts
- 7
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 21, 2023 | Noble Capital Markets | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 17, 2026
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
New York, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research. The update note includes detailed information on the MAIA Biotechnology’s business, recent updates, management commentary, financial results, valuatio
Benzinga · Aug 10, 2026
MAIA Biotechnology Q2 EPS $(0.13) Misses $(0.11) Estimate
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 27.78 percent increase over losses of $(0.18) per share
SeekingAlpha · Jul 27, 2026
Microsoft: Azure Skies, Premium Altitude
Microsoft Corporation faces AI CAPEX-driven margin pressure and FCF compression; valuation offers little safety. Click for this MSFT earnings preview.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
